37 studies found for:
" January 11, 2008":" February 08, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 21 | Completed |
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
|
||||
| 22 | Completed |
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
|
||||
| 23 | Unknown † |
Cognitive Stimulation Program in AIDS
|
||||
| 24 | Completed |
Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort
|
||||
| 25 | Completed |
Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population
|
||||
| 26 | Completed |
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
|
||||
| 27 | Unknown † |
Efficacy of Group Intervention to Reduce Stress Symptoms
|
||||
| 28 | Completed |
Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy
|
||||
| 29 | Completed |
Pharmacokinetic Study on Raltegravir and Lamotrigine
|
||||
| 30 | Completed |
Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis
|
||||
| 31 | Completed |
Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours
|
||||
| 32 | Completed |
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
|
||||
| 33 |
Completed
Has Results |
Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy
|
||||
| 34 | Active, not recruiting |
An Educational and Supportive Counseling Program for Increasing Antiretroviral Use and Adherence in People With HIV
|
||||
| 35 | Unknown † |
Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV
|
||||
| 36 | Active, not recruiting |
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
||||
| 37 | Terminated |
Effect of Omacor on Triglycerides in HIV Infected Subjects
|
† Indicates status has not been verified in more than two years
